PHARMASSISTANCE
ActiveFrom the official registers: KBO 32 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
PHARMASSISTANCE has been active since 1993 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€368,433) and a net result of -€1,501. Equity remains stable across the filed financial years (±0.2% per year). Its solvency ranks better than 5% of 10,798 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
Overview
Official details
KBO- Status
- Active since 10-03-1993 Normal situation
- Legal form
- Public limited company
- Registered office
- Doornboomstraat 5, 2440 Geel
- Activity
- Business and other management consultancy NACE 70200
- Establishment unit
- 2.102.886.952 2440 Geel, since 24-03-1993
- Financial year end
- 31 December
- Peppol
- Reachable since 26-09-2025
Who decides
- Mediphar InvestManaging director · permanent representative BOECKX Jozef Frans Dimphna
- VANHOUCKE Kristien Maria YvonneDirector
How it is doing
- Bankruptcy probabilitywithin 12 months
- 0.2%
- Gross margin
- €11,393
- ▲ 68.0%
- Turnover
- ≈ €46,000
- estimated
- Loss
- €1,501
- ▼ 77.9%
- Equity
- -€368,433
- ▼ 0.4%
- Total assets
- €28,893
- ▲ 28.1%
Why 53raises riskCapped at 59: negative equityNegative equity -€368,433lowers riskSize: total assets €28,893Sector: Activities of head offices; management consultancy activities (NACE 70)Founded in 1993Show the evidence
Checked score
About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro): better than 3% on solvency, 3% on liquidity, 14% on profitability and 38% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
This company filed its last 7 accounts on average 21 days after the deadline; the sector median (NACE 70) for financial year 2024 is 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Financials · financial year 2025, abbreviated format
Annual accounts 2025
- Financial year ended
- 31-12-2025
- Filed on
- 17-06-2026
- Format
- abbreviated format
- Reference
- 2026-00167333
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result recovers in 2025; 2025 is 105% above 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 70, Activities of head offices; management consultancy activities: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Current ratio, Return on assets (ROA).
Peer companies
Historical observationOf the 2,796 companies that looked in July 2024 the way this one looks now, 2.1% went bankrupt within 24 months and 90.4% are still going.
- Micro
- 20 years or older
- negative equity
- a small loss
A further 1.4% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a lower bankruptcy probability: 0.2% over twelve months. The score reads more about this company than the group's four characteristics; both figures are right about what they measure.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 2,796 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €580 | €0 | €678 | €692 | €692 | €692 | €1,200 | €1,291 | ▲ 7.6% |
| Other operating charges640/8 | - | - | - | €927 | €977 | €830 | €978 | €641 | ▼ 34.4% |
| Gross operating margin9900 | €12,906 | €13,846 | €17,445 | €4,028 | €588 | €11,157 | €6,782 | €11,393 | ▲ 68.0% |
| Operating profit (loss)9901 | €12,230 | €9,770 | €15,785 | €2,409 | -€1,081 | €9,635 | €4,604 | €9,460 | ▲ 105% |
| Financial income75/76B | - | - | - | €46 | €471 | €704 | €1,104 | €1,121 | ▲ 1.6% |
| Recurring financial income75 | €0 | €80 | €0 | €46 | €471 | €704 | €1,104 | €1,121 | ▲ 1.6% |
| Financial charges65/66B | - | - | - | €313 | €6,567 | €12,606 | €12,510 | €12,082 | ▼ 3.4% |
| Recurring financial charges65 | €304 | €4,132 | €1,163 | €313 | €6,567 | €12,606 | €12,510 | €12,082 | ▼ 3.4% |
| Profit (loss) for the period before taxes9903 | €11,926 | €5,717 | €14,622 | €2,143 | -€7,177 | -€2,267 | -€6,803 | -€1,501 | ▲ 77.9% |
| Income taxes67/77 | €0 | - | - | - | - | - | - | - | - |
| Profit (loss) for the period9904 | €11,926 | €5,717 | €14,622 | €2,143 | -€7,177 | -€2,267 | -€6,803 | -€1,501 | ▲ 77.9% |
| Profit (loss) for the period to be appropriated9905 | €11,926 | €5,717 | €14,622 | €2,143 | -€7,177 | -€2,267 | -€6,803 | -€1,501 | ▲ 77.9% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €12,682 | €274 | €19,745 | €18,332 | €14,005 | €24,226 | €22,549 | €28,893 | ▲ 28.1% |
| Formation expenses20 | €0 | - | - | - | - | - | - | - | - |
| Fixed assets21/28 | €0 | - | €6,237 | €5,545 | €4,854 | €4,162 | €4,761 | €3,470 | ▼ 27.1% |
| Intangible fixed assets21 | €0 | - | - | - | - | - | - | - | - |
| Tangible fixed assets22/27 | €0 | - | €6,237 | €5,545 | €4,854 | €4,162 | €4,761 | €3,470 | ▼ 27.1% |
| Plant, machinery and equipment23 | - | - | - | - | - | - | €1,290 | €691 | ▼ 46.5% |
| Other tangible fixed assets26 | - | - | - | €5,545 | €4,854 | €4,162 | €3,471 | €2,779 | ▼ 19.9% |
| Financial fixed assets28 | €0 | - | - | - | - | - | - | - | - |
| Current assets29/58 | €12,682 | €274 | €13,509 | €12,787 | €9,151 | €20,064 | €17,788 | €25,423 | ▲ 42.9% |
| Stocks and contracts in progress3 | €0 | - | - | - | - | - | - | - | - |
| Amounts receivable within one year40/41 | €12,070 | €0 | €12,261 | €5,878 | €8,315 | €19,297 | €17,119 | €24,246 | ▲ 41.6% |
| Trade receivables40 | - | - | - | €0 | €1,000 | €0 | - | - | - |
| Other amounts receivable41 | - | - | - | €5,878 | €7,315 | €19,297 | €17,119 | €24,246 | ▲ 41.6% |
| Current investments50/53 | €0 | - | - | - | - | - | - | - | - |
| Cash at bank and in hand54/58 | €612 | €274 | €991 | €6,863 | €364 | €767 | €670 | €1,177 | ▲ 75.7% |
| Deferred charges and accrued income490/1 | - | - | - | €46 | €471 | €0 | - | - | - |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €12,682 | €274 | €19,745 | €18,332 | €14,005 | €24,226 | €22,549 | €28,893 | ▲ 28.1% |
| Equity10/15 | -€373,169 | -€367,451 | -€352,829 | -€350,686 | -€357,862 | -€360,129 | -€366,932 | -€368,433 | ▼ 0.4% |
| Contributions10/11 | €105,000 | €105,000 | €105,000 | €105,000 | €105,000 | €105,000 | €105,000 | €105,000 | = |
| Capital10 | - | - | - | €105,000 | €105,000 | €105,000 | €105,000 | €105,000 | = |
| Issued capital100 | - | - | - | €105,000 | €105,000 | €105,000 | €105,000 | €105,000 | = |
| Reserves13 | €0 | - | - | - | - | - | - | - | - |
| Profit (loss) carried forward14 | -€478,169 | -€472,451 | -€457,829 | -€455,686 | -€462,862 | -€465,129 | -€471,932 | -€473,433 | ▼ 0.3% |
| Provisions and deferred taxes16 | €0 | - | - | - | - | - | - | - | - |
| Amounts payable17/49 | €385,851 | €367,725 | €372,574 | €369,018 | €371,867 | €384,355 | €389,482 | €397,327 | ▲ 2.0% |
| Amounts payable after more than one year17 | €47,662 | €54,962 | €54,962 | €54,962 | €54,962 | €54,962 | €54,962 | €54,962 | = |
| Financial debts170/4 | - | - | - | €54,962 | €54,962 | €54,962 | €54,962 | €54,962 | = |
| Amounts payable within one year42/48 | €338,189 | €312,763 | €317,612 | €314,056 | €316,905 | €329,394 | €334,520 | €342,356 | ▲ 2.3% |
| Trade debts44 | €22,031 | €3,256 | €11,218 | €11,091 | €7,952 | €11,220 | €6,117 | €5,761 | ▼ 5.8% |
| Suppliers440/4 | - | - | - | €11,091 | €7,952 | €11,220 | €6,117 | €5,761 | ▼ 5.8% |
| Advances received on contracts in progress46 | - | - | - | - | €1,000 | €0 | - | - | - |
| Taxes, remuneration and social security45 | - | - | - | €2,636 | €578 | €1,578 | €1,611 | €0 | ▼ 100% |
| Taxes450/3 | - | - | - | €2,636 | €578 | €1,578 | €1,611 | €0 | ▼ 100% |
| Other amounts payable47/48 | - | - | - | €300,330 | €307,375 | €316,596 | €326,792 | €336,595 | ▲ 3.0% |
| Accrued charges and deferred income492/3 | - | - | - | - | - | - | - | €9 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €11,926 | €5,717 | €14,622 | €2,143 | -€7,177 | -€2,267 | -€6,803 | -€1,501 | ▲ 77.9% |
| + Depreciation and write-downs630 | €580 | €0 | €678 | €692 | €692 | €692 | €1,200 | €1,291 | ▲ 7.6% |
| Operating cash flow (approximation) | €12,505 | €5,717 | €15,301 | €2,835 | -€6,485 | -€1,575 | -€5,603 | -€210 | ▲ 96.3% |
| Investment in fixed assets (approximation) | - | - | - | €0 | €0 | €0 | -€1,799 | €0 | - |
| Change in cash | - | -€338 | €717 | €5,872 | -€6,498 | €403 | -€97 | €507 | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 32 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 17-06-2026 | 2026-00167333 | NBB |
| 31-12-2024 | micro format | 01-07-2025 | 2025-00206015 | |
| 31-12-2023 | micro format | 05-07-2024 | 2024-00211791 | |
| 31-12-2022 | micro format | 08-08-2023 | 2023-00317992 | |
| 31-12-2021 | micro format | 31-08-2022 | 2022-20357232 | |
| 31-12-2020 | micro format | 01-10-2021 | 2021-69800047 | |
| 31-12-2019 | micro format | 24-12-2020 | 2020-76900267 | |
| 31-12-2018 | micro format | 28-08-2019 | 2019-54300349 | |
| 31-12-2017 | micro format | 28-08-2018 | 2018-52400051 | |
| 31-12-2016 | micro format | 20-07-2017 | 2017-34400570 |
Similar companies · same sector and region
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Board 1
Day-to-day management 1
Permanent representatives 1
Mandate history
- Board
- Day-to-day management
- began earlier
- end not dated
| Name | Functions and periods |
|---|---|
| VANHOUCKE Kristien Maria Yvonne |
|
| Mediphar Invest |
|
| BOECKX Jozef Frans Dimphna |
|
How the board is organised
- Board ruleHow the board is made up, meets and takes decisions.
- “Hoogstens zes jaar, te allen tijde en zonder opgave van redenen met onmiddellijke ingang door algemene vergadering”
- Dissolution ruleWhen and by whom the company can be dissolved.
- “Zoals inzake statutenwijziging, algemene vergadering”
Articles of association, deed of 11-12-2023 (in Dutch)
Owners and capital
Capital and shareholders
- 11-12-2023 Capital stated in the deed · €105,000 · 100 shares
Other provisions of the articles of association
- Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.
- Other provision: “Bevoegdheden raad van bestuur, alle handelingen nodig of dienstig tot verwezenlijking voorwerp”Other provision: “Juni, organisatie en bijeenroeping algemene vergadering”Other provision: “Regeling door jaarvergadering bij gewone meerderheid op voorstel raad van bestuur, bestemming winst”
Articles of association, deed of 11-12-2023 (in Dutch)
Group and network
Connections & network
1 connected companyThe connected companies are in the list below.
History
Acts, filings and financial milestones
11-12
Gazette deed
Resignations: VANHOUCKE Kristien Maria Yvonne (director) and Mediphar Invest (director)Reappointments: VANHOUCKE Kristien Maria Yvonne (director) and BOECKX Jozef Frans Dimphna (director) · Permanent representative: BOECKX Jozef Frans Dimphna · Appointment: Mediphar Invest (managing director)10 facts ▸
- General meeting, “buitengewone algemene vergadering” (deed in Dutch)
- Amendment of the articles (2 times)
- Capital, €105,000
- Director resignation, VANHOUCKE Kristien Maria Yvonne (director)
- Director reappointment, VANHOUCKE Kristien Maria Yvonne (director (not named in the articles))
- Director resignation, Mediphar Invest (director)
- Director reappointment, BOECKX Jozef Frans Dimphna (director (not named in the articles))
- Permanent representative, BOECKX Jozef Frans Dimphna (2 times)
- Director appointment, Mediphar Invest (managing director)
- Registered office clause, “2440 Geel,Doornboomstraat 5A, Vijfde besluit” (deed in Dutch)
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
Register details
Who it is
KBO recordWhere it is based
What it does
NACEBEL 2025Invoicing and payment
Financial year and general meeting
Accounts at the NBBScores and ratios are computed by Checked and are not a credit decision.
Purpose according to the articles of association
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- PHARMASSISTANCE
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaams Gewest, bestuursorgaan”
Articles of association, deed of 11-12-2023 (in Dutch)
Environmental permits: No permit applications found in Flanders.
Sites & property
1 establishment unit
Buildings and parcels at the address
1 parcel
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 13373L0601/00H000 | Flanders | 603 m² | 1 · 599 m² | 7.5 m · 2 |